• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    BeiGene Announces Closing of $800 Million Public Offering

    Gabrielle Lakusta
    Jan. 22, 2018 04:32PM PST
    Biotech Investing

    BeiGene (NASDAQ:BGNE) a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of its follow-on public offering of 7,920,800 American Depositary Shares each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of …

    BeiGene (NASDAQ:BGNE) a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced the closing of its follow-on public offering of 7,920,800 American Depositary Shares each representing 13 of its ordinary shares, par value $0.0001 per share, at a price to the public of $101.00 per ADS, for gross proceeds of approximately $800 million before deducting underwriting discounts and commissions and other offering expenses. This includes the full exercise of the underwriters’ option to purchase an additional 495,050 ADSs.
    As quoted in the press release:

    BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities.
    Goldman Sachs & Co. LLC, Morgan Stanley, Cowen, and Leerink Partners acted as joint book-running managers in this offering, and William Blair & Company, L.L.C. acted as co-manager.

    Click here to read the full press release.

    public offeringtreatment of canceramerican depositary sharescommercial-stage biopharmaceutical
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    Ă—